ASCO 2023
American Society of Clinical Oncology 2023 Annual Meeting
Advertisement
Dr. Kommalapati shares her thoughts on the association between tumor-informed MRD and clinical outcomes for MIBC.
Drs. Shilpa Gupta and Vadim Koshkin continue on the EV-103 trial with reference to outcomes and toxicities in cohort K.
Drs. Shilpa Gupta and Vadim Koshkin discuss the EV-103 trial and data, including long-term results for cohort A.
Tanya Jindal expands upon the UNITE study findings relative to biomarkers of response for SG and EV for advanced UC.
Dr. Hutson details the latest 4-year CLEAR data for patients who received 1L lenvatinib plus pembrolizumab for advanced RCC.
Dr. Hutson provides an overview of different combination therapies used and investigated for first-line advanced RCC.
Drs. Bossi and Wallis conclude with a breakdown of the right patients for radiotherapy when presenting with de novo mCSPC.
Drs. Bossi, Wallis address which patients with mCSPC experience synergistic effects from abiraterone plus radiotherapy.
Drs. Bossi and Wallis break down the results of the PEACE-1 study presented as an LBA at the ASCO Annual Meeting.
Dr. Albiges details the KEYMAKER-U03B study, outcomes for patients in arm B5, and next lines of research for belzutifan.
Drs. Loriot, Koshkin summarize erdafitinib versus chemotherapy in patients with advanced UC with select FGFR alterations.
Drs. Lee and McKay discuss the latest data on KEYNOTE-B61 for first-line lenvatinib plus pembrolizumab for nccRCC.
Dr. Miron provides an overview of clinical implications of molecular alterations in intraductal carcinoma of the prostate.
Drs. Powles and Koshkin break down the Q-TWiST analysis conducted on the JAVELIN Bladder 100 study for advanced UC.
Drs. Lerner and Koshkin explain the implications of the latest data from the SWOG S1011 study for mUC.
Drs. Friedlander and Koshkin highlight the 18-month data from the EV-103 study on EV/pembro first-line mUC treatment.
Drs. Siefker-Radtke and Koshkin detail the NORSE study design, results, and implications for treating patients with mUC.
Drs. Fizazi and Wallis detail the latest updates regarding TALAPRO-2 for patients with mCRPC and HRR gene alterations.
Drs. Rini and Wallis discuss the results of a late-breaking abstract on KEYNOTE-426, which now has long-term survival data.
The Oncology Brothers chat with Dr. Wallis on PARP inhibitors as well as neoadjuvant IO and EV for bladder cancer.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.